Skye Bioscience, Inc. (SKYE)

NASDAQ: SKYE · IEX Real-Time Price · USD
10.48
-0.30 (-2.78%)
Jun 14, 2024, 4:30 PM EDT - Market closed
-2.78%
Market Cap 294.15M
Revenue (ttm) n/a
Net Income (ttm) -37.50M
Shares Out 28.07M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 158,067
Open 10.40
Previous Close 10.78
Day's Range 10.15 - 11.07
52-Week Range 1.44 - 19.41
Beta 1.63
Analysts Buy
Price Target 22.00 (+109.92%)
Earnings Date n/a

About SKYE

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 11
Stock Exchange NASDAQ
Ticker Symbol SKYE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $22.0, which is an increase of 109.92% from the latest price.

Price Target
$22.0
(109.92% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session

A more conservative goal of $100 monthly dividend income would require owning 306 shares of Altria Group.

Other symbols: PERI
4 days ago - Benzinga

Skye Bioscience to discontinue development of eye disease treatment

Skye Bioscience said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study.

4 days ago - Reuters

Skye Bioscience to Present at Jefferies Global Healthcare Conference

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel ...

11 days ago - GlobeNewsWire

Skye Bioscience (SKYE) CEO on Drug Development

Skye Bioscience (SKYE) focuses on developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions. CEO Punit Dhillon joins Nicole Petallides to discuss th...

4 weeks ago - Schwab Network

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting

Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with n...

5 weeks ago - GlobeNewsWire

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

6 weeks ago - GlobeNewsWire

Skye Bioscience to Present at Upcoming Investment Conferences

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

7 weeks ago - GlobeNewsWire

Skye Bioscience Uplists to The Nasdaq Global Market

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial...

2 months ago - GlobeNewsWire

Skye Bioscience Announces $40 Million Private Placement Equity Financing

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. ...

3 months ago - Newsfile Corp

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial...

3 months ago - GlobeNewsWire

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commerciali...

3 months ago - GlobeNewsWire

Skye Bioscience to Present at Oppenheimer Investor Conference

San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercializ...

4 months ago - Newsfile Corp

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination wi...

4 months ago - Newsfile Corp

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile...

5 months ago - Newsfile Corp

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11...

6 months ago - GlobeNewsWire

Skye Bioscience Responds to OTC Markets Promotional Policy

San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid syst...

6 months ago - Newsfile Corp

Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endoca...

6 months ago - Newsfile Corp

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on ...

7 months ago - GlobeNewsWire

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address di...

7 months ago - Newsfile Corp

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, California--...

8 months ago - Newsfile Corp

CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Phase 1 clinical data to be released in conjunction with Investor Day This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc. San Diego, Califor...

8 months ago - Newsfile Corp

Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Phase 1 clinical data to be released in conjunction with Investor Day San Diego, California--(Newsfile Corp. - October 19, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pha...

8 months ago - Newsfile Corp

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will be reported in October San Diego, California--(Newsfile Corp. - September 27, ...

9 months ago - Newsfile Corp

Skye Bioscience Announces Participation at Upcoming Investor Conferences

San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate t...

9 months ago - Newsfile Corp

Skye Bioscience Reverse Stock Split to Be Effective on September 8th

San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid ...

10 months ago - Newsfile Corp